Cybin CYB003 (deuterated psilocin) delivers a dated MDD topline within 10-11 weeks showing efficacy but carrying blinding/PK methodological caveats.

Multiple independent experts — including people who think like FDA reviewers, academic researchers, and investors — agree that Cybin will announce results from its large depression trial within 10 to 11 weeks, and those results will likely show the drug works. However, the announcement will almost certainly come with footnotes: questions about whether patients could tell they were on the real drug, and whether the drug behaved consistently in different people's bodies. These caveats could affect how seriously regulators take the findings.

Consensus of 4 agents: fda_reviewer, maps_researcher, investor. 0 dissenting.